

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Security Interest in Exclusively Licensed Trademarks

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Endo Pharmaceuticals Inc.		06/17/2011	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	Morgan Stanley Senior Funding, Inc., as Administrative Agent
<b>Street Address:</b>	1 Pierrepont Plaza
<b>City:</b>	Brooklyn
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	11201
<b>Entity Type:</b>	CORPORATION: DELAWARE

**PROPERTY NUMBERS Total: 11**

Property Type	Number	Word Mark
Registration Number:	2936977	SANCTURA
Registration Number:	3547839	SANCTURA XR
Serial Number:	75924536	UROCIDIN
Registration Number:	1597110	LIDODERM
Registration Number:	2870973	LIDODERM
Registration Number:	2853072	LIDODERM
Registration Number:	1821958	TAKON
Registration Number:	3544556	
Registration Number:	0960282	VOLTAREN
Registration Number:	2828476	FROVA
Registration Number:	3281355	FROVA

**CORRESPONDENCE DATA**

Fax Number: (214)981-3400  
 Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

**900196453**

**TRADEMARK**  
**REEL: 004577 FRAME: 0228**

**CH \$290.00 2936977**

Phone: 214-981-3483  
Email: dclark@sidley.com  
Correspondent Name: Dusan Clark, Esq.  
Address Line 1: Sidley Austin LLP  
Address Line 2: 717 N. Harwood St., Suite 3400  
Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER:	40104-30030
-------------------------	-------------

NAME OF SUBMITTER:	Dusan Clark
--------------------	-------------

Signature:	/Dusan Clark/
------------	---------------

Date:	07/07/2011
-------	------------

**Total Attachments: 4**

source=Endo\_2011 EXECUTED CGSI Licensed Trademarks (EPI)#page1.tif  
source=Endo\_2011 EXECUTED CGSI Licensed Trademarks (EPI)#page2.tif  
source=Endo\_2011 EXECUTED CGSI Licensed Trademarks (EPI)#page3.tif  
source=Endo\_2011 EXECUTED CGSI Licensed Trademarks (EPI)#page4.tif

**CONFIRMATORY GRANT OF SECURITY INTEREST  
IN UNITED STATES TRADEMARKS**

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Confirmatory Grant") is made effective as of June 17, 2011 by and from ENDO PHARMACEUTICALS INC., a Delaware corporation (the "Grantor"), to and in favor of MORGAN STANLEY SENIOR FUNDING, INC., for itself and as Administrative Agent for the Secured Parties (as defined in the Credit Agreement referenced below) (in such capacities, the "Grantee").

WHEREAS, Endo Pharmaceuticals Holdings Inc. (the "Borrower"), the Lenders and the Grantee have entered into a Credit Agreement dated as of June 17, 2011 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement").

WHEREAS, the Grantor, along with certain other Subsidiaries of the Borrower, has guaranteed the repayment of the Secured Obligations pursuant to a Guaranty dated as of June 17, 2011 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Guaranty").

WHEREAS, the Borrower, the Grantor and certain Subsidiaries of the Borrower have entered into a Pledge and Security Agreement dated as of June 17, 2011 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement").

WHEREAS, the Grantor is the exclusive licensee of the trademarks listed on Exhibit A attached hereto (the "Trademarks"), which Trademarks are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been executed in conjunction with the security interest granted under the Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the Credit Agreement.

2) The Security Interest.

(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of (i) all the Secured Obligations and (ii) all of the obligations and liabilities of the Subsidiary Guarantors under the Guaranty. Upon the payment in full of all Secured Obligations (other than Unliquidated Obligations), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantor all reasonably requested instruments in writing releasing the security interest in the Trademarks acquired under the Security Agreement and this Confirmatory Grant.

(b) The Grantor hereby pledges and grants to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in all of the Grantor's right, title and interest in and to the

trademark registrations and trademark applications under and to the extent set forth in and permitted by the exclusive license to Grantor of such trademark registrations and trademark applications.

3) Governing Law. **THIS CONFIRMATORY GRANT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.**

\*\*\*\*\*

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant effective as of the date first written above.

ENDO PHAMACEUTICALS INC.

By: 

Name: David P. Holveck

Title: President and CEO

CONFIRMATORY GRANT OF SECURITY INTEREST  
IN UNITED STATES TRADEMARKS  
Exhibit A - SCHEDULE OF LICENSED TRADEMARKS

TRADEMARK	COUNTRY	STATUS	APP NO	APP DATE	REG NO	REG DATE	OWNER
SANCTURA	UNITED STATES	REGISTERED	78/256,069	9/14/2007	2936977	5/29/2005	Allergan, Inc.
SANCTURA	UNITED STATES	REGISTERED	78/256,069	5/29/2003	2936977	5/29/2005	Allergan, Inc.
SANCTURA XL	UNITED STATES	REGISTERED	77/279,791	9/14/2007	3547839	12/16/2008	Allergan, Inc.
SANCTURA XR	UNITED STATES	REGISTERED	77/279,791	9/14/2007	3547839	12/16/2008	Allergan, Inc.
UROCIDIN	UNITED STATES	PENDING	75/924,536	2/22/2000			Bioniche Life Sciences, Inc.
LIDODERM	UNITED STATES	REGISTERED	73/790,107	3/30/1989	1,597,110	5/22/1990	Hind Health Care, Inc.
LIDODERM	UNITED STATES	REGISTERED	76/487,897	2/6/2003	2,870,973	8/10/2004	Hind Health Care, Inc.
LIDODERM & Design	UNITED STATES	REGISTERED	76/522,165	6/12/2003	2,853,072	6/15/2004	Hind Health Care, Inc.
LIDODERM	MEXICO	REGISTERED	573211	10/31/2002	792,084	5/22/2003	Hind Health Care, Inc.
TAKON	UNITED STATES	REGISTERED	74/339,115	12/11/1992	1821958	2/15/1994	Hind Health Care, Inc.
DESIGN ONLY	UNITED STATES	REGISTERED	77/258,978	8/20/2007	3,544,556	12/9/2008	Novartis AG
VOLTAREN	UNITED STATES	REGISTERED	72/422,688	4/28/1972	0,960,282	6/5/1973	Novartis Corporation
FROVA	UNITED STATES	REGISTERED	78/017,693	7/20/2000	2,828,476	3/30/2004	VERNALIS DEVELOPMENT LIMITED
FROVA & Design	UNITED STATES	REGISTERED	76/668,676	11/7/2006	3,281,355	8/21/2007	VERNALIS DEVELOPMENT LIMITED

(Endo Pharmaceuticals Inc.)